CIRM Funded Clinical Trials

Phase 2 Open-Label Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe SLE With Lupus Nephritis

Disease Area:

Lupus Nephritis

Investigator:

Dr. Vaneet Sandhu

Institution:

Fate Therapeutics, Inc.

CIRM Grant:

CLIN2-20291 (Pre-Active)

Award Value:

$14,715,568.00

Trial Sponsor:

Fate Therapeutics, Inc.

Trial Stage:

Phase 2

Trial Status:

Launching

Targeted Enrollment:

N/A